– Four-year outcomes from the BICSTaR study further demonstrate the long-term efficacy and safety profile of Biktarvy®, providing insights for HIV clinical care
– New data on HIV treatment patterns reinforce the high barrier to resistance of Biktarvy
– Investigational regimens with once-daily, once-weekly and twice-yearly dosing frequencies across administration methods aim to expand options, help address unmet needs in HIV treatment and contribute to ending the global epidemic
Read the full press release here.
Source : Gilead Sciences, Inc.
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.